Latest Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of Generation Income Properties, Inc. common stock as of June 30, 2026.

Aristeia Capital, L.L.C. has filed a Schedule 13G, disclosing beneficial ownership of 2,203,396 warrants in OppFi Inc., representing 2.52% of the class.

Aristeia Capital, L.L.C. has filed a Schedule 13G, revealing beneficial ownership of 652,725 units in FortuneX Acquisition Corporation, representing approximately 7.55% of the outstanding securities.

Armistice Capital, LLC and Steven Boyd report acquiring a 9.99% beneficial ownership in FibroBiologics, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 713,539 ordinary shares, representing 4.99% of Evogene Ltd.'s outstanding shares.

Aristeia Capital, L.L.C. has disclosed beneficial ownership of 1,350,000 units, representing 5.30% of Praetorian Acquisition Corp.'s outstanding shares as of June 30, 2026.

Aristeia Capital, L.L.C. has disclosed a beneficial ownership of 2,178,000 units, representing 8.61% of the outstanding shares of Collective Acquisition Corp. II.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Estrella Immunopharma, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.99% of Enveric Biosciences, Inc. common stock.

Aristeia Capital, L.L.C. has filed a Schedule 13G, reporting beneficial ownership of 7.99% of ClearThink 1 Acquisition Corp.'s Class A ordinary shares as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,384,798 shares, representing 9.99% of Dogwood Therapeutics, Inc.'s common stock.

Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Small Cap Value Discovery Fund, have reported a combined beneficial ownership of 8.1% in Universal Electronics Inc. as of June 30, 2026.

Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Small Cap Value Discovery Fund, have reported a combined beneficial ownership of 8.1% in Universal Electronics Inc. as of June 30, 2026.

Armistice Capital, LLC, through its Master Fund, has acquired a 9.99% stake in Decoy Therapeutics Inc., signaling a notable investment in the company's common stock.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9,353,553 shares, representing 9.99% of Citius Oncology, Inc.'s common stock.

Madison Avenue International LP, along with affiliated entities, has reported a beneficial ownership of 9,212,252 ordinary shares, representing 17.7% of Theravance Biopharma, Inc.

Investment firm Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 1,592,863 shares, representing 9.53% of CervoMed Inc.'s common stock.

Readystate Asset Management, LP and its affiliates have disclosed a beneficial ownership of 10.7% of Azul S.A.'s American Depositary Shares, representing a significant investment.

Ameriprise Financial, Inc. has amended its Schedule 13G filing to reflect changes in its beneficial ownership of Personalis, Inc. common stock.

Ameriprise Financial, Inc. has amended its Schedule 13G filing to reflect changes in its beneficial ownership of Personalis, Inc. common stock.

Aristeia Capital, L.L.C. has filed an amendment to its Schedule 13G, reporting zero shares beneficially owned in Real Asset Acquisition Corp. as of June 30, 2026.

Brown Advisory Inc. and its subsidiaries have updated their Schedule 13G filing, reporting a combined beneficial ownership of 16.64% of Andersen Group Inc.'s Class A common stock as of June 30, 2026.

Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 559,706 shares, representing 9.99% of the outstanding common stock of Co-Diagnostics, Inc.

Aristeia Capital, L.L.C. has disclosed beneficial ownership of 1,000,000 Class A ordinary shares, representing 7.84% of the outstanding shares of ARC Group Acquisition I Corp.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Calidi Biotherapeutics, Inc. common stock.

Several Madison Avenue-affiliated entities and Eli Samaha have jointly reported beneficial ownership of 7.5% of Graham Holdings Company's Class B Common Stock as of June 30, 2026.

Baron Capital Group, Inc. and affiliated entities report a combined 7.57% beneficial ownership in Blackstone Digital Infrastructure Trust Inc. as of June 30, 2026.

Armistice Capital, LLC, through its Master Fund, has acquired a 9.99% stake in Change Agents Corporation, signaling a notable investment by the asset manager.

Aristeia Capital, L.L.C. has filed an amendment to its Schedule 13G, disclosing beneficial ownership of 1,034,023 Class A ordinary shares, representing 4.50% of the outstanding shares of Roman DBDR Acquisition Corp. II.

Aristeia Capital, L.L.C. has reported beneficial ownership of 1,283,186 Class A ordinary shares, representing 5.42% of the outstanding shares of Columbus Circle Capital Corp II.